Kent Jeff 4
4 · Horizon Therapeutics Public Ltd Co · Filed Nov 6, 2020
Insider Transaction Report
Form 4
Kent Jeff
See remarks
Transactions
- Sale
Ordinary Shares
2020-11-05$78.41/sh−27,194$2,132,170→ 71,799 total - Sale
Ordinary Shares
2020-11-05$81.62/sh−4,027$328,667→ 51,049 total - Sale
Ordinary Shares
2020-11-05$79.06/sh−15,573$1,231,212→ 56,226 total - Sale
Ordinary Shares
2020-11-05$80.53/sh−1,150$92,613→ 55,076 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2020.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.785 to $78.775 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.78 to $79.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.37 to $81.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.